Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

N/A

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02916745Phase 1Completed

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer

Role: lead

NCT03589456Terminated

Establishment of a PDT Patient Registry

Role: lead

NCT03344861Phase 1Completed

Safety of PDT-Photofrin® Prior to Lung Surgery

Role: lead

NCT03564054Not ApplicableTerminated

Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction

Role: collaborator

NCT02082522Phase 3Terminated

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

Role: lead

All 5 trials loaded